Skip to main content
Yabao Pharmaceutical Group Co.,Ltd logo

Yabao Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600351 ISIN · CNE000001CM5 LEI · 65560071PKRS4UHMVU53 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,360 across all filing types
Latest filing 2025-04-25 Governance Information
Country CN China
Listing Shanghai Stock Exchange 600351

About Yabao Pharmaceutical Group Co.,Ltd

http://www.yabao.com.cn

Yabao Pharmaceutical Group Co.,Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceutical products. The company maintains a specialized portfolio across therapeutic areas including pediatrics, cardiovascular health, and endocrinology. Key offerings include traditional Chinese medicines, chemical drugs, and innovative transdermal patches, such as the Dinggui Erqi Patch. The organization operates integrated production bases and research facilities dedicated to advancing drug delivery systems and biotechnological applications. Its business model emphasizes the modernization of traditional therapies alongside the development of conventional pharmaceuticals to address diverse clinical needs.

Recent filings

Filing Released Lang Actions
亚宝药业集团股份有限公司内部审计制度
Governance Information Classification · 95% confidence The document is titled as an internal audit system of a company, detailing the internal audit department's structure, responsibilities, procedures, and reporting requirements. It is a policy or governance document outlining internal audit practices rather than a financial report or announcement. It does not contain financial statements, earnings data, or voting results. It is not a report publication announcement or a certification. The content aligns with governance and internal control practices, focusing on audit procedures and internal control evaluation. Therefore, the document best fits the category of Governance Information (CGR).
2025-04-25 Chinese
亚宝药业集团股份有限公司股东会议事规则（2025年4月修订）
Governance Information Classification · 100% confidence The document is titled as "亚宝药业集团股份有限公司 股东会议事规则" which translates to "Rules of Procedure for Shareholders' Meetings of Yabao Pharmaceutical Group Co., Ltd." It details the procedures, powers, and regulations governing the conduct of shareholders' meetings, including the rights and responsibilities of shareholders, the board, and committees. It does not contain financial statements, earnings data, or any report of financial performance. Instead, it is a governance document outlining internal rules and procedures related to shareholder meetings. Therefore, it fits the category of Governance Information (CGR). The document length (8416 characters) and content confirm it is a full governance rules document, not a brief announcement or notice.
2025-04-25 Chinese
亚宝药业集团股份有限公司董事会议事规则（2025年4月修订）
Governance Information Classification · 100% confidence The document is titled as the "Rules of Procedure for the Board of Directors" of a company, detailing the internal governance, meeting procedures, voting rules, and responsibilities of the board members. It references relevant laws and stock exchange listing rules, and it is a governance document outlining how the board operates rather than a financial report or announcement. There is no indication of financial data, audit information, or shareholder voting results. It is not a report publication announcement or a certification. Therefore, the document fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-04-25 Chinese
亚宝药业董事会关于独立董事独立性情况的专项意见
Board/Management Information Classification · 95% confidence The document is a special opinion from the board regarding the independence of the company's independent directors, referencing regulatory requirements from the China Securities Regulatory Commission and the Shanghai Stock Exchange. It evaluates the independence of specific directors for the year 2024 and confirms compliance with relevant independence rules. This type of document is related to governance and board management information rather than a financial report or announcement of voting results. It does not contain financial data or earnings information, nor is it a report publication announcement. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on board matters, supporting this classification.
2025-04-25 Chinese
亚宝药业2024年内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the year 2024 by 亚宝药业集团股份有限公司. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2024, including financial and non-financial internal control defects, audit opinions, scope of evaluation, standards for defect recognition, and corrective actions. The content is detailed and specific to internal control evaluation rather than a full annual report or audit report. It is not a brief announcement or a certification letter but a substantive report on internal control evaluation. This type of document aligns with an Audit Report / Information (AR) category, which includes standalone audit reports and internal control evaluation results, excluding full annual reports. The document length (4254 characters) is sufficient to contain substantive content, not just an announcement. Therefore, the appropriate classification is AR with high confidence. FY 2024
2025-04-25 Chinese
亚宝药业集团股份有限公司关于控股股东部分股份解除质押的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the release of a portion of pledged shares by the controlling shareholder of the company. It details the number of shares released from pledge, the remaining pledged shares, and the shareholder's total holdings. There is no financial report, earnings data, or management discussion. The content focuses on share pledge status and related disclosures, which fits the category of Share Issue/Capital Change announcements. The document length is short and it is not a report publication or certification. Therefore, the appropriate classification is 'SHA' for Share Issue/Capital Change.
2025-04-18 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.